2026 Pharmaceutical Position Paper

The Committee on Pharmaceutical Affairs has issued a comprehensive set of policy recommendations aimed at bolstering Taiwan’s pharmaceutical supply resilience, ensuring the long-term sustainability of the National Health Insurance (NHI) system, and elevating the nation’s standing in the global healthcare market. As global political and economic shifts redefine international drug pricing and launch strategies, the Committee warns that Taiwan’s current regulatory and pricing structures must evolve to ensure Taiwanese patients maintain timely access to innovative therapies. The proposals emphasize deeper public-private collaboration and a strategic alignment with international standards to support the "Healthy Taiwan" vision championed by the current administration.

Strengthening the US-Taiwan Strategic Healthcare Partnership

At the heart of the Committee’s recommendations is the formalization of a U.S.-Taiwan pharmaceutical policy dialogue mechanism. This initiative builds upon recent diplomatic breakthroughs, most notably the agreement granting duty-free treatment in the U.S. market for Taiwanese generic drugs and active pharmaceutical ingredients (APIs). With the administration of President Lai Ching-te identifying biotechnology as one of the "Five Trusted Industries," there is a significant opportunity to attract increased U.S. investment into Taiwan’s domestic sector.

To sustain this momentum, the Committee advocates for an institutionalized exchange involving government officials, manufacturers, and academic experts. Such a platform would address critical topics including regulatory alignment, innovative medicine introduction, and pricing developments. Specifically, the Committee recommends that the National Health Insurance Administration (NHIA) conduct biannual consultations with industry stakeholders to review global economic trends. Beyond bilateral ties, the Committee suggests leveraging the Global Cooperation and Training Framework (GCTF) to showcase Taiwan’s healthcare governance strengths to a wider international audience.

Aligning Reimbursement with Global Clinical Standards

A central pillar of the "Healthy Taiwan" policy is the improvement of cancer care, with a specific goal of reducing cancer mortality rates. While the Committee commends the government’s commitment to aligning cancer drug reimbursement with international treatment guidelines, it notes that significant disparities remain. Current restrictions on patient eligibility, prior lines of treatment, and dosing durations for both cancer and non-cancer medicines often fall short of global benchmarks.

These gaps have dual consequences: they limit the ability of physicians to provide optimal care and discourage the participation of Taiwanese centers in international clinical trials. By failing to accumulate clinical experience on par with global peers, Taiwan risks undermining its competitiveness in the high-stakes world of medical research. The Committee urges an accelerated alignment of reimbursement conditions across all therapeutic areas to ensure that the domestic healthcare system remains a viable and attractive partner for global clinical development.

Financing Innovation through the Cancer Drugs Fund and Horizon Scanning

The introduction of innovative therapies is a primary driver of healthcare quality. The Committee welcomes the 2025 establishment of a dedicated Cancer Drugs Fund, which is expected to reach approximately NT$10 billion (US$312 million) once fully funded. However, the Committee emphasizes that the sustainability of this fund—and the broader NHI system—requires a shift from short-term financial controls to medium- and long-term evidence-based budgeting.

A key recommendation is the implementation of "horizon scanning," an early-awareness system that analyzes emerging medical technologies to anticipate future budget impacts. This proactive approach would allow the government to allocate resources with greater precision, ensuring that investment directions yield the intended health outcomes. Furthermore, the Committee stresses that regulatory revisions must protect existing incentives, such as pricing premiums for drugs that have undergone domestic clinical trials, to maintain Taiwan’s appeal to multinational pharmaceutical companies.

Reforming Drug Pricing to Maintain Launch Priority

Global pharmaceutical headquarters are increasingly scrutinizing pricing structures as they determine where to launch new products. To ensure Taiwan is not de-prioritized in global launch strategies, the Committee recommends that the NHI Pharmaceutical Reimbursement and Payment Standards adopt a pricing model based on the median of 10 reference countries.

Beyond simple reference pricing, the Committee advocates for value-based adjustments that account for clinical effectiveness, safety, and convenience. Special incentives should also be provided for therapies addressing unmet medical needs or for companies that establish research and development (R&D) centers or manufacturing bases within Taiwan. By creating a predictable and competitive market environment, Taiwan can reinforce its position as a trusted pharmaceutical hub in the Asia-Pacific region.

Improving Transparency and Predictability in Reimbursement Agreements

Pharmaceutical reimbursement agreements are essential tools for balancing patient access with financial sustainability. However, the Committee points out that current implementation often favors high rebates and hard spending caps, which can excessively compress prices. Because many countries now use international reference pricing, a low net price in Taiwan can negatively impact a drug’s pricing strategy in larger global markets.

The Committee calls for a framework based on procedural fairness and reasonable risk-sharing. This includes simplifying negotiation procedures, avoiding overly complex multi-layered agreements, and ensuring the strict confidentiality of contract terms. By fostering an environment of mutual trust and scientific calculation, Taiwan can encourage multinational firms to prioritize the local market for their most innovative offerings.

Chronology of Recent Pharmaceutical Policy Developments

The current push for reform follows a series of strategic moves by the Taiwanese government and international partners over the past 24 months:

• Mid-2023: The Ministry of Health and Welfare (MOHW) and NHIA pledge to gradually improve the drug pricing framework and engage in deeper dialogue with industry leaders.
• Late 2023: Significant breakthroughs in U.S.-Taiwan trade negotiations lead to duty-free status for Taiwanese generic drugs and APIs in the U.S. market.
• Early 2024: The Legislative Yuan completes amendments to Article 27 of the Pharmaceutical Affairs Act, shifting the focus from reactive shortage management to proactive risk mitigation.
• May 2024: President Lai Ching-te takes office, reaffirming the "Healthy Taiwan" vision and the inclusion of biotech in the "Five Trusted Industries" strategy.
• Late 2024 (Projected): Finalization of the 2025 NHI budget, including the initial allocations for the NT$10 billion Cancer Drugs Fund.

Lifecycle Management and the Drug Expenditure Target (DET) System

The Committee has raised concerns regarding the Drug Expenditure Target (DET) system, a budget control mechanism used to manage pharmaceutical spending. The baseline value for DET calculations has remained unchanged for over a decade, leading to an underestimation of actual expenditures and distorted pricing signals. This lack of recalibration can undermine supply stability and discourage the long-term presence of certain products in the market.

Furthermore, the Committee notes that current price protections are often limited to drugs with primary active-ingredient patents. This narrow definition is inconsistent with international patent standards and can lead to premature price reductions for innovative medicines that still hold valid secondary patents. Such practices diminish the lifecycle value of drugs and contribute to delays in new drug launches. The Committee urges the NHIA to recalibrate the DET baseline and expand the scope of patent recognition to align with global norms.

Data-Driven Supply Resilience and the Pharmaceutical Affairs Act

The amendment of Article 27 of the Pharmaceutical Affairs Act represents a significant step toward a more resilient supply chain. However, the Committee cautions that the subsequent regulations must be implemented with a risk-based approach. Imposing excessive administrative burdens on products with a history of stable supply could prove counterproductive.

The Committee recommends that reporting and notification requirements be differentiated based on the risk profile of the medication. Additionally, it emphasizes that forecast data provided by companies should be used for monitoring purposes rather than as a basis for punitive actions. Ongoing dialogue between the authority and industry is deemed essential to ensure that regulatory interventions remain necessary and minimally infringing on market operations.

Analysis of Implications for Taiwan’s Global Standing

The proposed reforms carry significant implications for Taiwan’s economic and public health trajectory. By aligning with international standards, Taiwan can transform from a market characterized by pricing pressures into a premier destination for biomedical innovation.

1. Clinical Trial Leadership: Aligning reimbursement with international guidelines will naturally increase the volume of clinical trials conducted in Taiwan, providing local patients with early access to cutting-edge therapies and boosting the expertise of the domestic medical community.
2. Economic Growth: Integrating the pharmaceutical sector into the "Five Trusted Industries" framework will likely trigger a surge in foreign direct investment, particularly from U.S.-based biotech firms looking for stable, high-tech partners in Asia.
3. Patient Outcomes: A more resilient supply chain and a robust Cancer Drugs Fund will directly translate to better survival rates and quality of life for patients, fulfilling the core promise of the "Healthy Taiwan" initiative.
4. Regional Influence: As Taiwan refines its NHI system and pharmaceutical regulations, it serves as a model for other nations grappling with the balance of universal healthcare and the high costs of innovation, thereby enhancing its "soft power" in global health diplomacy.

The Committee concludes that the window of opportunity is open for Taiwan to harmonize its domestic policies with global trends. Through a combination of regularized dialogue, fair pricing mechanisms, and proactive supply management, the government can ensure that the NHI system remains a sustainable pillar of society while driving the nation toward a future of healthcare excellence and international competitiveness.